Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5322662 | 0.88 | PPARG (0.52) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL5323366 | 0.82 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL497439 | 0.82 | CYP2D6 (0.49) | CYP2D6SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL22338831 | 0.82 | CYP2D6 (0.49) | CYP2D6SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1162118 | 0.82 | CYP2D6 (0.49) | CYP2D6SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL839858 | 0.80 | CYP2D6 (0.47) | SLC6A2SLC6A4SLC6A3CYP2D6SLC1A3 | |
| SCHEMBL19650503 | 0.80 | UGT2B7 (0.53) | SLC1A3SLC1A2SLC1A1AKR1C3AKR1C2 | |
| SCHEMBL7363110 | 0.80 | UGT2B7 (0.53) | SLC1A3SLC1A2SLC1A1AKR1C3AKR1C2 | |
| SCHEMBL5455403 | 0.80 | UGT2B7 (0.53) | SLC1A3SLC1A2SLC1A1AKR1C3AKR1C2 | |
| SCHEMBL5319511 | 0.80 | UGT2B7 (0.53) | SLC1A3SLC1A2SLC1A1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143052-B2 | Process for preparing optically active (S or R)-α amino acid and (R or S)-α amino acid ester in one phase organic reaction medium | UBE INDUSTRIES, LTD. (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | SLC6A2 3882/4885SLC6A4 3604/4885SLC6A3 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.